Investor News

Gentian Diagnostics announces results from a study comparing the levels of the biomarker calprotectin with the biomarkers procalcitonin (PCT) and heparin binding protein (HBP)

Moss, 02.10.2018

Gentian Diagnostics AS is pleased to announce that today the results from a study comparing the levels of the biomarker calprotectin with the biomarkers procalcitonin (PCT) and heparin binding protein (HBP) was published at the International Sepsis Forum in Bangkok. All adult patients with arterial cannula that where primarily admitted to the mixed ICU at Östersund General Hospital between the 1st of February 2012 and 31st of January 2013 were screened for discharge diagnoses. Plasma taken on admission from patients was analysed for Calprotectin, and the more investigated sepsis biomarkers Heparin Binding Protein (HBP) and Procalcitonin. (HBP) and Procalcitonin. The study compared levels of these biomarkers in patients with sepsis (defined according to Sepsis 2) with levels in patients admitted for trauma, i.e. controls with inflammation, patients with other medical conditions (OMC), i.e. medical admissions with no infection, and finally with medical and surgical patients without these pre-specified diagnoses (Miscellaneous conditions). 328 patients met the inclusion criteria and Calprotectin performed best in discrimination between patients with sepsis and trauma patients and the conclusion from this study is that Calprotectin may be superior to Procalcitonin and HBP in indicating patients with sepsis as calprotectin, unlike HBP and procalcitonin, was consistently higher in sepsis patients compared to patients with other diagnoses with and without systemic inflammation. Calprotectin performed better then PCT and HBP in diagnosis of sepsis and distinguishing between patients with sepsis and trauma patients. Calprotectin and HBP showed predictive ability regarding 30 days mortality. Procalcitonin did not. Sepsis is the leading cause of death in ICU with a continuously increasing incidence and a high mortality rate. Early treatment improves outcome suggesting that rapid identification of patients with sepsis is important. The study was conducted in collaboration with Karolinska Institute, Uppsala University and Umeå University.

Please see the research poster for further information: Research Poster ISF_2018

For further information, please contact

Hilja Ibert
CEO, Gentian Diagnostics AS
E-mail: hilja.ibert@gentian.no
+47 919 05 242

Njaal Kind
CFO, Gentian Diagnostics AS
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

 

Gentian Diagnostics has obtained proof of concept for a new product for Exocrine Pancreatic Insufficiency and monitoring of pancreatic function

Moss, 22.06.2018

Gentian Diagnostics (OSE: GENT-ME) is pleased to announce that it has achieved proof of
concept on turbidimetric measurement of Fecal Pancreatic Elastase (fPELA). The project was
initiated in November 2017 in collaboration with Gentian’s established partner BÜHLMANN
Laboratories AG in Basel.
The test to be developed from this concept is a measure of Pancreatic Exocrine Insufficiency
(PEI) associated with various health conditions, e.g. chronic pancreatitis, cystic fibrosis, celiac
disease, diabetes, post-pancreatic surgery, gastrectomy etc.
fPELA testing today is only commercially available on ELISA platforms, and testing is likely
to increase if available on highly automated, high throughput chemistry analyzers. If successful,
Gentian and its partner BÜHLMANN estimates that the annual test volume could reach 5 to 10
Mio tests annually ex USA.
Commenting on the news, CEO Thomas Hafen in Bühlmann Laboratories AG says:
“Accompanied by Gentian BÜHLMANN already has commercialized fCAL©turbo, and we are
experiencing strong growth. The combination of fCAL©turbo and an fPELA turbo test will
significantly strengthen our market position, even more as fCAL and fPELA will be measured
from the very same stool extract in CALEX© Cap. (BÜHLMANN’ s proprietary fecal sample
tube)”
CEO in Gentian, Bård Sundrehagen adds: “Based on the highly successful cooperation between
Gentian and BÜHLMANN over the past 6 years, we have now signed an exclusive cooperation
agreement comprising development of fPELA and worldwide distribution on the same platforms
as for fCAL© turbo.”

 

For further information, please contact:
Bård Sundrehagen
CEO, Gentian Diagnostics AS
E-mail: bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117

Njaal Kind
CFO, Gentian Diagnostics AS
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525

 

Gentian Diagnostics is nominated for the Star of Innovation Award
Gentian is proud to announce the nomination as one of three companies for the Star of Innovation Award, one of the categories of the European Small and Mid-Cap Awards.

“The champion of the Star of Innovation prize will be a newly listed mid-cap company that places innovation at the centre of its strategy for business development. Candidates vying for the award may be introducing innovative technology to the market, or using innovative techniques in its day-to-day operations. The winner should be well-managed and successful in its sector. The Jury will pay particular attention to the future potential that the innovation offers.” (https://europeansmallandmidcapawards.eu)

european small and mid cap awards

 

Corporate presentation
Read more about Gentian in the corporate presentation from December 2016.